LOGIN  |  REGISTER
C4 Therapeutics
Terns Pharmaceuticals

Revvity Highlights its Strong Progress on Sustainability and Workplace Culture in 2024 Impact Report

October 22, 2024 | Last Trade: US$93.72 1.82 -1.90

WALTHAM, Mass. / Oct 22, 2024 / Business Wire / Revvity, Inc. (NYSE: RVTY) today unveils its annual Impact Report, a declaration of the Company’s sustainability, social and governance strategy, initiatives and performance. The report showcases Revvity’s continued evolution and strengthened commitments to creating a lasting, positive impact on the world.

“Whether it’s from developing groundbreaking solutions that drive positive health outcomes or through our sustainability initiatives, such as reducing waste and carbon emissions, we are making substantial strides in creating a healthier, cleaner and more inclusive world for generations to come,“ said Prahlad Singh, president and chief executive officer at Revvity. “The duly named Impact Report represents a purpose-driven shift for Revvity to a holistic, sustainable business approach – one that underlies our approach across the entire company.”

The report shares how the Company is positively impacting the environment and society through its responsible business philosophy and operations. Below are several highlights:

  • Achieved a -7% reduction in Scope 1 and 2 emissions in 2023, ahead of plan towards achieving longer-term goals.
  • Implemented a sustainability due diligence program covering the majority of annual direct material supplier spend.
  • Achieved 75% employee satisfaction in 2023 with 85% employee participation in an employee experience survey.
  • Maintained approximately 40% female representation across leadership positions.
  • Expanded audited gender pay gap collection and analysis to additional countries with further expansion expected over the next 12 months.
  • Introduced new corporate policies covering key emerging topics including ethical artificial intelligence, sustainable procurement, and cyber risk management, amongst others.
  • Created and funded new Revvity Access STEM Scholarships with Northeastern University and University of California San Diego to help support the development of the next generation of scientists.

To learn more about Revvity’s commitments and progress visit esg.revvity.com.

About Revvity

At Revvity, “impossible” is inspiration, and “can’t be done” is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more.

With 2023 revenue of more than $2.7 billion and over 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&P 500 index and has customers in more than 190 countries.

Stay updated by following our Newsroom, LinkedIn, X, YouTube, Facebook and Instagram.

C4 Therapeutics

Stock Quote

Featured Stock

Amneal Pharmaceuticals

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE

Featured Stock

Recursion

Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page